Alessandra Graziano1, Flaviana Bianco1, Adele D'Amico1, Isabella Moroni1, Sonia Messina1, Claudio Bruno1, Elena Pegoraro1, Marina Mora1, Guja Astrea1, Francesca Magri1, Giacomo P Comi1, Angela Berardinelli1, Maurizio Moggio1, Lucia Morandi1, Antonella Pini1, Roberta Petillo1, Giorgio Tasca1, Mauro Monforte1, Carlo Minetti1, Tiziana Mongini1, Enzo Ricci1, Ksenija Gorni1, Roberta Battini1, Marcello Villanova1, Luisa Politano1, Francesca Gualandi1, Alessandra Ferlini1, Francesco Muntoni1, Filippo Maria Santorelli1, Enrico Bertini1, Marika Pane1, Eugenio Mercuri2. 1. From the Departments of Paediatrics and Neurology (A.G., F.B., G.T., M. Monforte, E.R., M.P., E.M.), Catholic University, Rome; Unit of Neuromuscular and Neurodegenerative Disorders (A.D., G.T., E.B.), Department of Neurosciences, Bambino Gesù Children's Hospital, Rome; Pediatric Neurology and Neuromuscular Disease and Immunology Unit (I.M., M. Mora, L.M.), Istituto Neurologico Besta, Milan; Department of Neurosciences, Psychiatry and Anaesthesiology (S.M.), University of Messina; Neuromuscular Disease Unit (C.B., C.M.), G. Gaslini Institute, Genoa; Department of Neurosciences (E.P.), University of Padua, Italy; Department of Developmental Neuroscience and Molecular Medicine Neuromuscular Unit (G.A., R.B., F.M.S.), Stella Maris Institute, Pisa; Department of Neurological Sciences (F. Magri, G.P.C.), IRCCS Ospedale Maggiore Policlinico, University of Milan; Child Neurology and Psychiatry Unit (A.B.), IRCCS C. Mondino Foundation; Neuromuscular and Rare Diseases Unit (M. Moggio), IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Milano; Child Neurology and Psychiatry Unit (A.P.), IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna; Cardiomiologia e Genetica Medica (R.P., L.P.), Dipartimento di Medicina Sperimentale Seconda Università di Napoli; Neuromuscular Center (T.M.), S.G. Battista Hospital, University of Turin; Centro Nemo (K.G.), Milan; Neuromuscular Unit (M.V.), Nigrisoli Hospital, Bologna; Section of Medical Genetics (F.G., A.F.), Department of Experimental and Diagnostic Medicine, Ferrara, Italy; and Dubowitz Neuromuscular Centre (F. Muntoni), UCL Institute of Child Health & Great Ormond Street Hospital for Children, London, UK. 2. From the Departments of Paediatrics and Neurology (A.G., F.B., G.T., M. Monforte, E.R., M.P., E.M.), Catholic University, Rome; Unit of Neuromuscular and Neurodegenerative Disorders (A.D., G.T., E.B.), Department of Neurosciences, Bambino Gesù Children's Hospital, Rome; Pediatric Neurology and Neuromuscular Disease and Immunology Unit (I.M., M. Mora, L.M.), Istituto Neurologico Besta, Milan; Department of Neurosciences, Psychiatry and Anaesthesiology (S.M.), University of Messina; Neuromuscular Disease Unit (C.B., C.M.), G. Gaslini Institute, Genoa; Department of Neurosciences (E.P.), University of Padua, Italy; Department of Developmental Neuroscience and Molecular Medicine Neuromuscular Unit (G.A., R.B., F.M.S.), Stella Maris Institute, Pisa; Department of Neurological Sciences (F. Magri, G.P.C.), IRCCS Ospedale Maggiore Policlinico, University of Milan; Child Neurology and Psychiatry Unit (A.B.), IRCCS C. Mondino Foundation; Neuromuscular and Rare Diseases Unit (M. Moggio), IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Milano; Child Neurology and Psychiatry Unit (A.P.), IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna; Cardiomiologia e Genetica Medica (R.P., L.P.), Dipartimento di Medicina Sperimentale Seconda Università di Napoli; Neuromuscular Center (T.M.), S.G. Battista Hospital, University of Turin; Centro Nemo (K.G.), Milan; Neuromuscular Unit (M.V.), Nigrisoli Hospital, Bologna; Section of Medical Genetics (F.G., A.F.), Department of Experimental and Diagnostic Medicine, Ferrara, Italy; and Dubowitz Neuromuscular Centre (F. Muntoni), UCL Institute of Child Health & Great Ormond Street Hospital for Children, London, UK. mercuri@rm.unicatt.it.
Abstract
OBJECTIVE: We provide a nationwide population study of patients with congenital muscular dystrophy in Italy. METHODS: Cases were ascertained from the databases in all the tertiary referral centers for pediatric neuromuscular disorders and from all the genetic diagnostic centers in which diagnostic tests for these forms are performed. RESULTS: The study includes 336 patients with a point prevalence of 0.563 per 100,000. Mutations were identified in 220 of the 336 (65.5%). The cohort was subdivided into diagnostic categories based on the most recent classifications on congenital muscular dystrophies. The most common forms were those with α-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin α2 deficiency (24.11%) and collagen VI deficiency (20.24%). The forms of congenital muscular dystrophy related to mutations in SEPN1 and LMNA were less frequent (6.25% and 5.95%, respectively). CONCLUSIONS: Our study provides for the first time comprehensive epidemiologic information and point prevalence figures for each of the major diagnostic categories on a large cohort of congenital muscular dystrophies. The study also reflects the diagnostic progress in this field with an accurate classification of the cases according to the most recent gene discoveries.
OBJECTIVE: We provide a nationwide population study of patients with congenital muscular dystrophy in Italy. METHODS: Cases were ascertained from the databases in all the tertiary referral centers for pediatric neuromuscular disorders and from all the genetic diagnostic centers in which diagnostic tests for these forms are performed. RESULTS: The study includes 336 patients with a point prevalence of 0.563 per 100,000. Mutations were identified in 220 of the 336 (65.5%). The cohort was subdivided into diagnostic categories based on the most recent classifications on congenital muscular dystrophies. The most common forms were those with α-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin α2 deficiency (24.11%) and collagen VI deficiency (20.24%). The forms of congenital muscular dystrophy related to mutations in SEPN1 and LMNA were less frequent (6.25% and 5.95%, respectively). CONCLUSIONS: Our study provides for the first time comprehensive epidemiologic information and point prevalence figures for each of the major diagnostic categories on a large cohort of congenital muscular dystrophies. The study also reflects the diagnostic progress in this field with an accurate classification of the cases according to the most recent gene discoveries.
Authors: K M Flanigan; L Kerr; M B Bromberg; C Leonard; J Tsuruda; P Zhang; I Gonzalez-Gomez; R Cohn; K P Campbell; M Leppert Journal: Ann Neurol Date: 2000-02 Impact factor: 10.422
Authors: R A Peat; J M Smith; A G Compton; N L Baker; R A Pace; D J Burkin; S J Kaufman; S R Lamandé; K N North Journal: Neurology Date: 2007-12-26 Impact factor: 9.910
Authors: F M Tomé; T Evangelista; A Leclerc; Y Sunada; E Manole; B Estournet; A Barois; K P Campbell; M Fardeau Journal: C R Acad Sci III Date: 1994-04
Authors: M Villanova; E Mercuri; E Bertini; P Sabatelli; L Morandi; M Mora; C Sewry; M Brockington; S C Brown; A Ferreiro; N M Maraldi; T Toda; P Guicheney; L Merlini; F Muntoni Journal: Neuromuscul Disord Date: 2000-12 Impact factor: 4.296
Authors: Carsten G Bönnemann; Ching H Wang; Susana Quijano-Roy; Nicolas Deconinck; Enrico Bertini; Ana Ferreiro; Francesco Muntoni; Caroline Sewry; Christophe Béroud; Katherine D Mathews; Steven A Moore; Jonathan Bellini; Anne Rutkowski; Kathryn N North Journal: Neuromuscul Disord Date: 2014-01-09 Impact factor: 4.296
Authors: Alec R Nickolls; Michelle M Lee; Kristen Zukosky; Barbara S Mallon; Carsten G Bönnemann Journal: Dis Model Mech Date: 2020-06-26 Impact factor: 5.758